Peroxisome Proliferator Activated Receptors and Lipoprotein Metabolism
Figure 1
The PPAR agonist Wy14643 dramatically lowers VLDL production in a mouse model of
hypertriglyceridemia. Male Angptl4-transgenic mice ( per group) were given
vehicle or Wy14643 for 10 days (0.1% mixed in their food). After a 24-hour fast,
the LPL-inhibitor tyloxapol (Triton WR1339, 500 mg/kg bodyweight as 15%
solution in saline) or saline were injected intraorbitally. (a) Plasma
triglyceride concentration was measured every 30 minutes to determine the VLDL
production rate. (b) Mean rate of increase of plasma TG concentration in mice
that received tyloxapol. Differences were evaluated by Student’s t-test ().
Error bars represent SEM.
